Fatal hepatitis C associated fibrosing cholestatic hepatitis as a complication of cyclophosphamide and corticosteroid treatment of active glomerulonephritis.
Fibrosing cholestatic hepatitis (FCH) is an aggressive and usually fatal form of viral hepatitis in immunocompromised patients. It is characterized by progressive cholestasis leading to hepatic failure, and a characteristic histopathological features including: periportal fibrosis, ballooning degeneration of hepatocytes, cholestasis, with minimal inflammation. FCH has been reported almost exclusively in heavily immunosuppressed organ transplant recipients or patients with AIDS. This case report describes a previously immunocompetent patient with previously stable chronic hepatitis C who developed fibrosing cholestatic hepatitis after receiving cyclophosphamide and corticosteroids for active glomerulonephritis.
Saleh
Faisal
F
Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
Ko
Hin Hin
HH
Davis
Jennifer E
JE
Apiratpracha
Wichian
W
Powell
James J
JJ
Erb
Siegfried R
SR
Yoshida
Eric M
EM
D000305:Adrenal Cortex Hormones / Q000009:adverse effects* / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000009:adverse effects* / Q000627:therapeutic use; D018450:Disease Progression; D017809:Fatal Outcome; D005260:Female; D005921:Glomerulonephritis / Q000188:drug therapy*; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000139:chemically induced* / Q000473:pathology; D008875:Middle Aged